Title Published Date
Sanovas Fills Corporate Bench with Industry Veterans in Clinical, Regulatory and Finance 11 September 2012
Sanovas Forms Scientific Advisory Board to Support Development of Lung Cancer Technology Former University of Maryland Medical Center CEO Dr. Stephen C. Schimpff joins as Chairman 25 July 2012
Sanovas Secures First U.S. Patent for Microinvasive Lung Cancer Technology 15 June 2012
Frost & Sullivan Recognizes Sanovas for its Path-Breaking Innovation in the Treatment of Pulmonary Disease 12 June 2012
Sanovas Wins North American Medical Device New Product Innovation Award ! 25 May 2012
Sanovas CEO Larry Gerrans Featured at BayBio's 'Fundraising in Troubled Times' 24 January 2012
Sanovas Expands Headquarters and Opens Manufacturing Site 24 January 2012
Science, Government and Industry Converge in National Call to Action on Lung Cancer 10 August 2011
Sanovas Video Animation Illustrates Revolutionary Advances in Interventional Pulmonology Disease Solutions 27 July 2011
NIH-funded study shows 20 percent reduction in lung cancer mortality with low-dose CT compared to chest X-ray 28 June 2011
Sanovas’ Completes Finalization of Initial ‘Go To Market’ Technology Platform 06 February 2011
Sanovas on Capitol Hill 18 January 2011
Sanovas Awarded the Qualifying Therapeutic Drug Discovery Grant 30 November 2010
King and Spalding retained as Sanovas FDA Counsel 03 November 2010
Sanovas Invited to Participate in AdvaMed’s Emerging Growth Company Council 01 September 2010
FDA REGULATORY DISCLOSURE: Sanovas Inc. is an emerging technology company.
These products are investigational medical devices that have not been approved or cleared for use in the United States.